NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Vital Therapies, Inc. (NASDAQ:VTL) resulting from allegations that Vital Therapies may have issued materially misleading business information to the investing public.
On July 14, 2015, Seeking Alpha published a report alleging that Vital Therapies’ representations concerning the 90 day overall survival rate for those treated with the Vital Therapies’ Extracorporeal Liver Assist Device (“ELAD”) were highly misleading, because they included survival data from a patient who underwent liver transplant surgery. However, no comparable patient in the control group had received a transplant. The report alleges that this fact was not divulged through Vital Therapies’ previous disclosures regarding the Phase 2 VTI-206 study of ELAD. On this news, shares of Vital Therapies fell $3.61 per share or over 13% to close at $23.10 per share on July 15, 2015.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Vital Therapies investors. If you purchased shares of Vital Therapies on or before July 14, 2015, please visit the firm’s website at http://rosenlegal.com/cases-671.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
